-
1
-
-
51649091675
-
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes
-
Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008, 26:4124-4130.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4124-4130
-
-
Vose, J.1
Armitage, J.2
Weisenburger, D.3
-
2
-
-
30144443996
-
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001
-
Morton L.M., Wang S.S., Devesa S.S., Hartge P., Weisenburger D.D., Linet M.S. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276.
-
(2006)
Blood
, vol.107
, pp. 265-276
-
-
Morton, L.M.1
Wang, S.S.2
Devesa, S.S.3
Hartge, P.4
Weisenburger, D.D.5
Linet, M.S.6
-
3
-
-
18444404649
-
The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas
-
Sonnen R., Schmidt W.P., Muller-Hermelink H.K., Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005, 129:366-372.
-
(2005)
Br J Haematol
, vol.129
, pp. 366-372
-
-
Sonnen, R.1
Schmidt, W.P.2
Muller-Hermelink, H.K.3
Schmitz, N.4
-
4
-
-
79953124083
-
Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
-
Weisenburger D.D., Savage K.J., Harris N.L., et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011, 117:3402-3408.
-
(2011)
Blood
, vol.117
, pp. 3402-3408
-
-
Weisenburger, D.D.1
Savage, K.J.2
Harris, N.L.3
-
5
-
-
84879126115
-
Treatment strategies for peripheral T-cell lymphomas
-
Foss F.M. Treatment strategies for peripheral T-cell lymphomas. Best Pract Res Clin Haematol 2013, 26:43-56.
-
(2013)
Best Pract Res Clin Haematol
, vol.26
, pp. 43-56
-
-
Foss, F.M.1
-
6
-
-
18044383718
-
Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience
-
Escalon M.P., Liu N.S., Yang Y., et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005, 103:2091-2098.
-
(2005)
Cancer
, vol.103
, pp. 2091-2098
-
-
Escalon, M.P.1
Liu, N.S.2
Yang, Y.3
-
7
-
-
77956046528
-
Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group
-
Gressin R., Caulet-Maugendre S., Deconinck E., et al. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica 2010, 95:1350-1357.
-
(2010)
Haematologica
, vol.95
, pp. 1350-1357
-
-
Gressin, R.1
Caulet-Maugendre, S.2
Deconinck, E.3
-
8
-
-
0032870340
-
CHOP versus MACOP-B in aggressive lymphoma-a Nordic Lymphoma Group randomised trial
-
Jerkeman M., Anderson H., Cavallin-Stahl E., et al. CHOP versus MACOP-B in aggressive lymphoma-a Nordic Lymphoma Group randomised trial. Ann Oncol 1999, 10:1079-1086.
-
(1999)
Ann Oncol
, vol.10
, pp. 1079-1086
-
-
Jerkeman, M.1
Anderson, H.2
Cavallin-Stahl, E.3
-
9
-
-
78049508777
-
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group
-
Schmitz N., Trumper L., Ziepert M., et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010, 116:3418-3425.
-
(2010)
Blood
, vol.116
, pp. 3418-3425
-
-
Schmitz, N.1
Trumper, L.2
Ziepert, M.3
-
10
-
-
10744224285
-
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma
-
Tilly H., Lepage E., Coiffier B., et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003, 102:4284-4289.
-
(2003)
Blood
, vol.102
, pp. 4284-4289
-
-
Tilly, H.1
Lepage, E.2
Coiffier, B.3
-
11
-
-
84869088219
-
The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives
-
Yared J., Kimball A. The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives. Cancer Treat Rev 2013, 39:51-59.
-
(2013)
Cancer Treat Rev
, vol.39
, pp. 51-59
-
-
Yared, J.1
Kimball, A.2
-
12
-
-
0037093068
-
Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma
-
Gisselbrecht C., Lepage E., Molina T., et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002, 20:2472-2479.
-
(2002)
J Clin Oncol
, vol.20
, pp. 2472-2479
-
-
Gisselbrecht, C.1
Lepage, E.2
Molina, T.3
-
13
-
-
0033890745
-
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - A Groupe d'Etude des Lymphomes de l'Adulte Study
-
Haioun C., Lepage E., Gisselbrecht C., et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - A Groupe d'Etude des Lymphomes de l'Adulte Study. J Clin Oncol 2000, 18:3025-3030.
-
(2000)
J Clin Oncol
, vol.18
, pp. 3025-3030
-
-
Haioun, C.1
Lepage, E.2
Gisselbrecht, C.3
-
14
-
-
19944425806
-
All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
-
Mounier N., Gisselbrecht C., Briere J., et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 2004, 15:1790-1797.
-
(2004)
Ann Oncol
, vol.15
, pp. 1790-1797
-
-
Mounier, N.1
Gisselbrecht, C.2
Briere, J.3
-
15
-
-
34047159303
-
The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience
-
Rodriguez J., Conde E., Gutierrez A., et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007, 18:652-657.
-
(2007)
Ann Oncol
, vol.18
, pp. 652-657
-
-
Rodriguez, J.1
Conde, E.2
Gutierrez, A.3
-
16
-
-
34347266576
-
Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group
-
Rodriguez J., Conde E., Gutierrez A., et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007, 79:32-38.
-
(2007)
Eur J Haematol
, vol.79
, pp. 32-38
-
-
Rodriguez, J.1
Conde, E.2
Gutierrez, A.3
-
17
-
-
58149347800
-
Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study
-
Reimer P., Rudiger T., Geissinger E., et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009, 27:106-113.
-
(2009)
J Clin Oncol
, vol.27
, pp. 106-113
-
-
Reimer, P.1
Rudiger, T.2
Geissinger, E.3
-
18
-
-
43049095718
-
Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma
-
Mercadal S., Briones J., Xicoy B., et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008, 19:958-963.
-
(2008)
Ann Oncol
, vol.19
, pp. 958-963
-
-
Mercadal, S.1
Briones, J.2
Xicoy, B.3
-
19
-
-
84865712593
-
Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01
-
d'Amore F., Relander T., Lauritzsen G.F., et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012, 30:3093-3099.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3093-3099
-
-
d'Amore, F.1
Relander, T.2
Lauritzsen, G.F.3
-
20
-
-
84892556579
-
Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation
-
Gkotzamanidou M., Papadimitriou C.A. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation. Crit Rev Oncol Hematol 2013, 10.1016/j.critrevonc.2013.08.016.
-
(2013)
Crit Rev Oncol Hematol
-
-
Gkotzamanidou, M.1
Papadimitriou, C.A.2
-
21
-
-
84891076403
-
Peripheral T-cell lymphomas: a review of current approaches and hopes for the future
-
Skarbnik A.P., Burki M., Pro B. Peripheral T-cell lymphomas: a review of current approaches and hopes for the future. Front Oncol 2013, 3:138.
-
(2013)
Front Oncol
, vol.3
, pp. 138
-
-
Skarbnik, A.P.1
Burki, M.2
Pro, B.3
-
22
-
-
84884727679
-
The aggressive peripheral T-cell lymphomas: 2013
-
Armitage J.O. The aggressive peripheral T-cell lymphomas: 2013. Am J Hematol 2013, 88:910-918.
-
(2013)
Am J Hematol
, vol.88
, pp. 910-918
-
-
Armitage, J.O.1
-
23
-
-
84885843319
-
Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma
-
Czajczynska A., Gunther A., Repp R., et al. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2013, 19:1632-1637.
-
(2013)
Biol Blood Marrow Transplant
, vol.19
, pp. 1632-1637
-
-
Czajczynska, A.1
Gunther, A.2
Repp, R.3
-
24
-
-
84875527567
-
Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma
-
Kanakry J.A., Kasamon Y.L., Gocke C.D., et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant 2013, 19:602-606.
-
(2013)
Biol Blood Marrow Transplant
, vol.19
, pp. 602-606
-
-
Kanakry, J.A.1
Kasamon, Y.L.2
Gocke, C.D.3
-
25
-
-
84862130917
-
Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR
-
e1
-
Hale G.A., Shrestha S., Le-Rademacher J., et al. Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. Biol Blood Marrow Transplant 2012, 18:1036-1043. e1.
-
(2012)
Biol Blood Marrow Transplant
, vol.18
, pp. 1036-1043
-
-
Hale, G.A.1
Shrestha, S.2
Le-Rademacher, J.3
-
26
-
-
79952229727
-
Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas
-
Reimer P. Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas. Adv Hematol 2010, 2010:320624.
-
(2010)
Adv Hematol
, vol.2010
, pp. 320624
-
-
Reimer, P.1
-
27
-
-
79955029799
-
Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma)
-
Dearden C.E., Johnson R., Pettengell R., et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol 2011, 153:451-485.
-
(2011)
Br J Haematol
, vol.153
, pp. 451-485
-
-
Dearden, C.E.1
Johnson, R.2
Pettengell, R.3
-
28
-
-
47049084821
-
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
-
Savage K.J., Harris N.L., Vose J.M., et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008, 111:5496-5504.
-
(2008)
Blood
, vol.111
, pp. 5496-5504
-
-
Savage, K.J.1
Harris, N.L.2
Vose, J.M.3
-
29
-
-
84876966952
-
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
-
Mosse Y.P., Lim M.S., Voss S.D., et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol 2013, 14:472-480.
-
(2013)
Lancet Oncol
, vol.14
, pp. 472-480
-
-
Mosse, Y.P.1
Lim, M.S.2
Voss, S.D.3
-
30
-
-
46749135265
-
Extranodal NK/T-cell lymphoma: diagnosis and treatment cues
-
Suzuki R., Takeuchi K., Ohshima K., Nakamura S. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol 2008, 26:66-72.
-
(2008)
Hematol Oncol
, vol.26
, pp. 66-72
-
-
Suzuki, R.1
Takeuchi, K.2
Ohshima, K.3
Nakamura, S.4
-
31
-
-
84872198307
-
Current and future management of NK/T-cell lymphoma based on clinical trials
-
Yamaguchi M. Current and future management of NK/T-cell lymphoma based on clinical trials. Int J Hematol 2012, 96:562-571.
-
(2012)
Int J Hematol
, vol.96
, pp. 562-571
-
-
Yamaguchi, M.1
-
32
-
-
33644835980
-
Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma
-
Li Y.X., Yao B., Jin J., et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006, 24:181-189.
-
(2006)
J Clin Oncol
, vol.24
, pp. 181-189
-
-
Li, Y.X.1
Yao, B.2
Jin, J.3
-
33
-
-
84869456017
-
Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211
-
Yamaguchi M., Tobinai K., Oguchi M., et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol 2012, 30:4044-4046.
-
(2012)
J Clin Oncol
, vol.30
, pp. 4044-4046
-
-
Yamaguchi, M.1
Tobinai, K.2
Oguchi, M.3
-
34
-
-
34250659715
-
CMED in the treatment of nasal natural killer cell lymphoma with distant metastases
-
Aviles A., Cleto S., Castaneda C., Nambo M.J. CMED in the treatment of nasal natural killer cell lymphoma with distant metastases. Hematology 2007, 12:241-244.
-
(2007)
Hematology
, vol.12
, pp. 241-244
-
-
Aviles, A.1
Cleto, S.2
Castaneda, C.3
Nambo, M.J.4
-
35
-
-
43649085643
-
Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia
-
Yamaguchi M., Suzuki R., Kwong Y.L., et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008, 99:1016-1020.
-
(2008)
Cancer Sci
, vol.99
, pp. 1016-1020
-
-
Yamaguchi, M.1
Suzuki, R.2
Kwong, Y.L.3
-
36
-
-
84867810745
-
SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group
-
Kwong Y.L., Kim W.S., Lim S.T., et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012, 120:2973-2980.
-
(2012)
Blood
, vol.120
, pp. 2973-2980
-
-
Kwong, Y.L.1
Kim, W.S.2
Lim, S.T.3
-
37
-
-
81755172136
-
Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study
-
Yamaguchi M., Kwong Y.L., Kim W.S., et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011, 29:4410-4416.
-
(2011)
J Clin Oncol
, vol.29
, pp. 4410-4416
-
-
Yamaguchi, M.1
Kwong, Y.L.2
Kim, W.S.3
-
38
-
-
79951483189
-
Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study
-
Jaccard A., Gachard N., Marin B., et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011, 117:1834-1839.
-
(2011)
Blood
, vol.117
, pp. 1834-1839
-
-
Jaccard, A.1
Gachard, N.2
Marin, B.3
-
39
-
-
33645210475
-
Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors
-
Yong W., Zheng W., Zhu J., et al. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Hematol Oncol 2006, 24:28-32.
-
(2006)
Hematol Oncol
, vol.24
, pp. 28-32
-
-
Yong, W.1
Zheng, W.2
Zhu, J.3
-
40
-
-
79957938142
-
Enteropathy-associated T-cell lymphoma
-
Ferreri A.J., Zinzani P.L., Govi S., Pileri S.A. Enteropathy-associated T-cell lymphoma. Crit Rev Oncol Hematol 2011, 79:84-90.
-
(2011)
Crit Rev Oncol Hematol
, vol.79
, pp. 84-90
-
-
Ferreri, A.J.1
Zinzani, P.L.2
Govi, S.3
Pileri, S.A.4
-
41
-
-
84858653535
-
How I treat enteropathy-associated T-cell lymphoma
-
Di Sabatino A., Biagi F., Gobbi P.G., Corazza G.R. How I treat enteropathy-associated T-cell lymphoma. Blood 2012, 119:2458-2468.
-
(2012)
Blood
, vol.119
, pp. 2458-2468
-
-
Di Sabatino, A.1
Biagi, F.2
Gobbi, P.G.3
Corazza, G.R.4
-
42
-
-
77952578954
-
Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation
-
Sieniawski M., Angamuthu N., Boyd K., et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010, 115:3664-3670.
-
(2010)
Blood
, vol.115
, pp. 3664-3670
-
-
Sieniawski, M.1
Angamuthu, N.2
Boyd, K.3
-
43
-
-
33847339853
-
Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells
-
Al-toma A., Visser O.J., van Roessel H.M., et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood 2007, 109:2243-2249.
-
(2007)
Blood
, vol.109
, pp. 2243-2249
-
-
Al-toma, A.1
Visser, O.J.2
van Roessel, H.M.3
-
44
-
-
34948824913
-
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
-
Gallamini A., Zaja F., Patti C., et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007, 110:2316-2323.
-
(2007)
Blood
, vol.110
, pp. 2316-2323
-
-
Gallamini, A.1
Zaja, F.2
Patti, C.3
-
45
-
-
84993707686
-
Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
-
Marchi E, O'Connor OA. Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Ther Adv Hematol;3:227-35.
-
Ther Adv Hematol
, vol.3
, pp. 227-35
-
-
Marchi, E.1
O'Connor, O.A.2
-
47
-
-
0037409795
-
Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression
-
Wang E.S., O'Connor O., She Y., Zelenetz A.D., Sirotnak F.M., Moore M.A. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003, 44:1027-1035.
-
(2003)
Leuk Lymphoma
, vol.44
, pp. 1027-1035
-
-
Wang, E.S.1
O'Connor, O.2
She, Y.3
Zelenetz, A.D.4
Sirotnak, F.M.5
Moore, M.A.6
-
48
-
-
32944480860
-
The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma
-
Toner L.E., Vrhovac R., Smith E.A., et al. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res 2006, 12:924-932.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 924-932
-
-
Toner, L.E.1
Vrhovac, R.2
Smith, E.A.3
-
49
-
-
77954755959
-
Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies
-
Marchi E., Paoluzzi L., Scotto L., et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res 2010, 16:3648-3658.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 3648-3658
-
-
Marchi, E.1
Paoluzzi, L.2
Scotto, L.3
-
50
-
-
70349310325
-
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies
-
O'Connor O.A., Horwitz S., Hamlin P., et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009, 27:4357-4364.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4357-4364
-
-
O'Connor, O.A.1
Horwitz, S.2
Hamlin, P.3
-
51
-
-
79952749741
-
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study
-
O'Connor O.A., Pro B., Pinter-Brown L., et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011, 29:1182-1189.
-
(2011)
J Clin Oncol
, vol.29
, pp. 1182-1189
-
-
O'Connor, O.A.1
Pro, B.2
Pinter-Brown, L.3
-
52
-
-
84871758096
-
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial
-
Damaj G., Gressin R., Bouabdallah K., et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol 2013, 31:104-110.
-
(2013)
J Clin Oncol
, vol.31
, pp. 104-110
-
-
Damaj, G.1
Gressin, R.2
Bouabdallah, K.3
-
53
-
-
84881090160
-
Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma
-
Hassler M.R., Schiefer A.I., Egger G. Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma. Epigenomics 2013, 5:397-415.
-
(2013)
Epigenomics
, vol.5
, pp. 397-415
-
-
Hassler, M.R.1
Schiefer, A.I.2
Egger, G.3
-
54
-
-
2942535832
-
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance
-
Piekarz R.L., Robey R.W., Zhan Z., et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004, 103:4636-4643.
-
(2004)
Blood
, vol.103
, pp. 4636-4643
-
-
Piekarz, R.L.1
Robey, R.W.2
Zhan, Z.3
-
55
-
-
79952977561
-
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
-
Piekarz R.L., Frye R., Prince H.M., et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011, 117:5827-5834.
-
(2011)
Blood
, vol.117
, pp. 5827-5834
-
-
Piekarz, R.L.1
Frye, R.2
Prince, H.M.3
-
57
-
-
84892910948
-
A phase Ib/II trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL): the Ro-CHOP study
-
[abstract 18]
-
Dupuis J., Morschhauser F., Ghesquieres H., et al. A phase Ib/II trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL): the Ro-CHOP study. Hematol Oncol 2013, 31(Suppl 1):135. [abstract 18].
-
(2013)
Hematol Oncol
, vol.31
, Issue.SUPPL. 1
, pp. 135
-
-
Dupuis, J.1
Morschhauser, F.2
Ghesquieres, H.3
-
58
-
-
84884558230
-
Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): results from the BELIEF trial
-
[abstract 8507]
-
O'Connor O., Masszi T., Savage K., et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): results from the BELIEF trial. J Clin Oncol 2013, 31(Suppl). [abstract 8507].
-
(2013)
J Clin Oncol
, vol.31
, Issue.SUPPL.
-
-
O'Connor, O.1
Masszi, T.2
Savage, K.3
-
59
-
-
84872107995
-
Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial
-
Duvic M., Dummer R., Becker J.C., et al. Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 2013, 49:386-394.
-
(2013)
Eur J Cancer
, vol.49
, pp. 386-394
-
-
Duvic, M.1
Dummer, R.2
Becker, J.C.3
-
60
-
-
34547660727
-
Expression of CD52 in peripheral T-cell lymphoma
-
Piccaluga P.P., Agostinelli C., Righi S., Zinzani P.L., Pileri S.A. Expression of CD52 in peripheral T-cell lymphoma. Haematologica 2007, 92:566-567.
-
(2007)
Haematologica
, vol.92
, pp. 566-567
-
-
Piccaluga, P.P.1
Agostinelli, C.2
Righi, S.3
Zinzani, P.L.4
Pileri, S.A.5
-
61
-
-
84859984909
-
Overview of alemtuzumab therapy for the treatment of T-cell lymphomas
-
Zinzani P.L., Corradini P., Gallamini A., et al. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Leuk Lymphoma 2012, 53:789-795.
-
(2012)
Leuk Lymphoma
, vol.53
, pp. 789-795
-
-
Zinzani, P.L.1
Corradini, P.2
Gallamini, A.3
-
62
-
-
1842579580
-
A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
-
Enblad G., Hagberg H., Erlanson M., et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004, 103:2920-2924.
-
(2004)
Blood
, vol.103
, pp. 2920-2924
-
-
Enblad, G.1
Hagberg, H.2
Erlanson, M.3
-
63
-
-
34247397835
-
Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study
-
Kim J.G., Sohn S.K., Chae Y.S., et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007, 60:129-134.
-
(2007)
Cancer Chemother Pharmacol
, vol.60
, pp. 129-134
-
-
Kim, J.G.1
Sohn, S.K.2
Chae, Y.S.3
-
64
-
-
84879007299
-
Linked-in: design and efficacy of antibody drug conjugates in oncology
-
Feld J., Barta S.K., Schinke C., Braunschweig I., Zhou Y., Verma A.K. Linked-in: design and efficacy of antibody drug conjugates in oncology. Oncotarget 2013, 4:397-412.
-
(2013)
Oncotarget
, vol.4
, pp. 397-412
-
-
Feld, J.1
Barta, S.K.2
Schinke, C.3
Braunschweig, I.4
Zhou, Y.5
Verma, A.K.6
-
65
-
-
10744222473
-
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
-
Doronina S.O., Toki B.E., Torgov M.Y., et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003, 21:778-784.
-
(2003)
Nat Biotechnol
, vol.21
, pp. 778-784
-
-
Doronina, S.O.1
Toki, B.E.2
Torgov, M.Y.3
-
66
-
-
78049515807
-
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
-
Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363:1812-1821.
-
(2010)
N Engl J Med
, vol.363
, pp. 1812-1821
-
-
Younes, A.1
Bartlett, N.L.2
Leonard, J.P.3
-
67
-
-
84863678237
-
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study
-
Pro B., Advani R., Brice P., et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012, 30:2190-2196.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2190-2196
-
-
Pro, B.1
Advani, R.2
Brice, P.3
-
68
-
-
84862126172
-
Mogamulizumab: first global approval
-
Subramaniam J.M., Whiteside G., McKeage K., Croxtall J.C. Mogamulizumab: first global approval. Drugs 2012, 72:1293-1298.
-
(2012)
Drugs
, vol.72
, pp. 1293-1298
-
-
Subramaniam, J.M.1
Whiteside, G.2
McKeage, K.3
Croxtall, J.C.4
-
69
-
-
77951916883
-
Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma
-
Yamamoto K., Utsunomiya A., Tobinai K., et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010, 28:1591-1598.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1591-1598
-
-
Yamamoto, K.1
Utsunomiya, A.2
Tobinai, K.3
-
70
-
-
84863393084
-
Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study
-
Ishida T., Joh T., Uike N., et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012, 30:837-842.
-
(2012)
J Clin Oncol
, vol.30
, pp. 837-842
-
-
Ishida, T.1
Joh, T.2
Uike, N.3
-
71
-
-
84892927850
-
The efficacy and safety of mogamulizumab (KW-0761) in multicentre phase II study for patients with relapsed peripheral or cutaneous T-cell lymphoma
-
[abstract 41]
-
Ueda R., Ogura M., Ishida T., et al. The efficacy and safety of mogamulizumab (KW-0761) in multicentre phase II study for patients with relapsed peripheral or cutaneous T-cell lymphoma. Hematol Oncol 2013, 31(Suppl 1):109. [abstract 41].
-
(2013)
Hematol Oncol
, vol.31
, Issue.SUPPL. 1
, pp. 109
-
-
Ueda, R.1
Ogura, M.2
Ishida, T.3
-
72
-
-
84876414545
-
Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma
-
Ishida T., Ito A., Sato F., et al. Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci 2013, 104:647-650.
-
(2013)
Cancer Sci
, vol.104
, pp. 647-650
-
-
Ishida, T.1
Ito, A.2
Sato, F.3
-
73
-
-
77953347770
-
Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
-
Kaminetzky D., Hymes K.B. Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Biologics 2008, 2:717-724.
-
(2008)
Biologics
, vol.2
, pp. 717-724
-
-
Kaminetzky, D.1
Hymes, K.B.2
-
74
-
-
33846010137
-
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma
-
Dang N.H., Pro B., Hagemeister F.B., et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007, 136:439-447.
-
(2007)
Br J Haematol
, vol.136
, pp. 439-447
-
-
Dang, N.H.1
Pro, B.2
Hagemeister, F.B.3
-
75
-
-
79952263752
-
Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial
-
[abstract 8045]
-
Foss F., Sjak-Shie N., Goy A., Advani R., Jacobsen E. Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial. J Clin Oncol 2010, Suppl:15s:28. [abstract 8045].
-
(2010)
J Clin Oncol
, vol.15 S
, pp. 28
-
-
Foss, F.1
Sjak-Shie, N.2
Goy, A.3
Advani, R.4
Jacobsen, E.5
-
76
-
-
77957566161
-
Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma
-
Dueck G., Chua N., Prasad A., et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010, 116:4541-4548.
-
(2010)
Cancer
, vol.116
, pp. 4541-4548
-
-
Dueck, G.1
Chua, N.2
Prasad, A.3
-
77
-
-
84881109532
-
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial
-
Morschhauser F., Fitoussi O., Haioun C., et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer 2013, 49:2869-2876.
-
(2013)
Eur J Cancer
, vol.49
, pp. 2869-2876
-
-
Morschhauser, F.1
Fitoussi, O.2
Haioun, C.3
-
78
-
-
84892916318
-
Phase II study of alisertib, a selective aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas
-
Friedberg J.W., Mahadevan D., Cebula E., et al. Phase II study of alisertib, a selective aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol 2014, 32:44-50.
-
(2014)
J Clin Oncol
, vol.32
, pp. 44-50
-
-
Friedberg, J.W.1
Mahadevan, D.2
Cebula, E.3
-
79
-
-
84872456641
-
Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the International Peripheral T-Cell Lymphoma Project
-
Federico M., Rudiger T., Bellei M., et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the International Peripheral T-Cell Lymphoma Project. J Clin Oncol 2013, 31:240-246.
-
(2013)
J Clin Oncol
, vol.31
, pp. 240-246
-
-
Federico, M.1
Rudiger, T.2
Bellei, M.3
|